Reforgene named a 2024 Top 50 most influential healthcare company
On May 15, 2025, the "2024 Annual China Healthcare Industry Investment and Financing Honor List" was officially announced. With its innovative technology R&D strength, forward-looking strategic layout and industry-leading practices, Reforgene was listed among the "2024 Top 50 Most Influential Healthcare Enterprises", demonstrating its comprehensive competitiveness and sustainable development potential in the healthcare field. This edition particularly focused on enterprises' performance in core technology breakthroughs, global market expansion and inclusive healthcare practices, emphasizing both the sustainable growth of commercial value and substantive contributions to the construction of the public health system. Reforgene demonstrated strong technological innovation capability, strong disruptive technology attributes and rapid response to clinical needs, providing an innovative paradigm for the industry to learn from.
The additional honor is further evidence that capital markets and industry institutions unanimously favor Reforgene's innovative development. In the future, with continued policy support and capital resources, Reforgene is expected to keep breaking through in technology and model innovation, bring curative solutions to more diseases, and contribute Chinese wisdom to the global health cause.
China Healthcare Industry Investment and Financing Honor List
The "Annual China Healthcare Industry Investment and Financing Honor List" was jointly initiated by CHC Medical Consulting and CITIC Securities, focusing on five core dimensions: technological innovation, capital empowerment, commercialization progress, social responsibility and industry synergy. Through multiple rounds of review and cross-validation, it systematically evaluates enterprises' value creation capability and industry influence in the healthcare field. This edition covered key tracks including pharmaceutical R&D, high-end medical devices, digital health and medical services, aiming to discover benchmark enterprises that promote industry upgrading and solve clinical needs, injecting new momentum into industry development.
About Reforgene
Reforgene Medicine is one of China’s leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. Reforgene has a high-caliber team that applied gene editing to explore the treatment of genetic diseases at an early stage internationally, and has accumulated pioneering achievements in hematology, ophthalmology and other disease areas, with strong technical capabilities in gene editing tool innovation, drug development strategy, novel animal model construction, and multi-level efficacy and safety assessment, operating both in vivo and ex vivo drug development. Reforgene’s mission is to deliver accessible, curative medicines for patients with serious diseases through innovative genetic technologies. The company currently has pipeline programs across genetic diseases, complex diseases and oncology. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, it achieved the world’s first cure of an alpha-thalassemia patient, and the IND application for its first-in-class Usher syndrome gene editing medicine has been approved by regulators in both China and the United States.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.